Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Health Policy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    169 result(s) found for: Health Policy. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2006-001443-63 Sponsor Protocol Number: 01062 Start Date*: 2006-07-10
    Sponsor Name:European Lung Cancer Working Party
    Full Title: A phase II study assessing the activity of valproate acid plus doxorubicin in refractory or recurrent malignant mesothelioma.
    Medical condition: This is a prospective phase II study investigating well-known antimetabolite (doxorubicin) and antiepileptic (valproate) drugs, in combination, for the treatment of refractory or recurrent malignan...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007182-23 Sponsor Protocol Number: MenOccy/I72P1 Start Date*: 2010-03-16
    Sponsor Name:Health Protection Agency
    Full Title: A phase 2, open-label study of the safety, tolerability and immunogenicity of a Novartis meningococcal B vaccine when administered at a 0, 2, 6 month schedule and of a single dose of Novartis menin...
    Medical condition: The study investigates the ability of the two vaccines to induce protective immunity against meningococcal disease.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001589-25 Sponsor Protocol Number: BN29854 Start Date*: 2015-11-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Multicenter, open-label, single-arm study to evaluate long term safety, tolerability, and effectiveness of 10mg/kg BID olesoxime in patients with Spinal Muscular Atrophy
    Medical condition: Spinal Muscular Atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10051203 Spinal muscular atrophy congenital LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) DE (Completed) BE (Completed) NL (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002877-27 Sponsor Protocol Number: CTRIAL-IE-21-29/NRG-GY019 Start Date*: 2023-07-06
    Sponsor Name:Cancer Trials Ireland
    Full Title: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or P...
    Medical condition: Primary low-grade serous carcinoma of the ovary or peritoneum.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007107 Cancer of ovary LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026340 Malignant neoplasm of peritoneum, unspecified LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000423-13 Sponsor Protocol Number: GX30191 Start Date*: 2016-10-25
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HA...
    Medical condition: Geographic Atrophy secondary to age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000161390 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) AT (Completed) SE (Completed) DE (Prematurely Ended) PL (Prematurely Ended) ES (Completed) SK (Prematurely Ended) BE (Prematurely Ended) FR (Completed) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001384-87 Sponsor Protocol Number: WN29722 Start Date*: 2020-10-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE PHARMACODYNAMIC EFFECTS OF ONCE WEEKLY ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH EARLY (PRODOMAL TO MILD) ALZHEIMER'S...
    Medical condition: Alzheimer's Disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    20.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) BE (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000766-42 Sponsor Protocol Number: WN42171 Start Date*: 2020-07-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF LONG-TERM GANTENERUMAB ADMINISTRATION IN PARTICIPANTS WITH ALZHEIMER'S DISEASE
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    20.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) PT (Prematurely Ended) PL (Prematurely Ended) HU (Completed) DE (Completed) FR (Ongoing) IT (Prematurely Ended) LT (Ongoing) NL (Completed) BE (Completed) FI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000072-17 Sponsor Protocol Number: BH30071 Start Date*: 2016-06-30
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH...
    Medical condition: Haemophilia A without factor VIII inhibitors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10053753 Hemophilia A without inhibitors LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) ES (Ongoing) DE (Completed) PL (Completed) FR (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-001731-20 Sponsor Protocol Number: ML29741 Start Date*: 2016-03-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A SINGLE ARM, OPEN LABEL, PHASE II, MULTICENTER STUDY TO ASSESS THE DETECTION OF THE BRAF V600 MUTATION ON cfDNA FROM PLASMA IN PATIENTS WITH ADVANCED MELANOMA
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000759-41 Sponsor Protocol Number: MO39136 Start Date*: 2018-08-30
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE II TWO COHORT STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB PLUS ATEZOLIZUMAB IN BRAFV600 WILD-TYPE MELANOMA WITH CENTRAL NERVOUS SYSTEM METASTASES AND COBIMETINIB PLUS ATEZOLIZU...
    Medical condition: Metastatic Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) HU (Completed) ES (Completed) DE (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-003256-32 Sponsor Protocol Number: MO42245 Start Date*: 2021-04-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN INTERVENTIONAL OPEN-LABEL MULTICENTER PHASE IV STUDY TO EVALUATE THE IMPACT OF EMICIZUMAB ON HEALTH-RELATED QUALITY OF LIFE, PHYSICAL ACTIVITY, AND JOINT HEALTH IN PATIENTS WITH SEVERE HEMOPHILI...
    Medical condition: Severe hemophilia A without factor VIII inhibitors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10053753 Hemophilia A without inhibitors LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: SE (Ongoing) NO (Ongoing) FI (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002179-32 Sponsor Protocol Number: BO41423 Start Date*: 2019-10-15
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB IN PATIENTS WITH MILD OR MODERATE HEMOPHILIA A WITHOUT FVIII INHIBITORS
    Medical condition: Mild or moderate hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10053753 Hemophilia A without inhibitors LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) DE (Ongoing) NL (Ongoing) PL (Completed) BE (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001364-38 Sponsor Protocol Number: WN29922 Start Date*: 2018-06-18
    Sponsor Name:Roche Farma S.A.(Soc. Unipersonal)que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche LTD
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER'S DISEASE
    Medical condition: Alzheimer’s Disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    20.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) BE (Completed) LT (Completed) DE (Completed) HU (Completed) DK (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004184-39 Sponsor Protocol Number: BP39054 Start Date*: 2017-09-05
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS/PHARMACODYNAMICS OF RO7034067 IN ADULT AND PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Ongoing) DE (Completed) FR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001365-24 Sponsor Protocol Number: WN39658 Start Date*: 2018-06-05
    Sponsor Name:Roche Farma S.A.(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F.Hoffmann-La Roche LTD
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER’S DISEASE
    Medical condition: Alzheimer’s Disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    20.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (GB - no longer in EU/EEA) DK (Completed) BE (Completed) PT (Prematurely Ended) PL (Prematurely Ended) NL (Prematurely Ended) SE (Completed) FI (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001733-12 Sponsor Protocol Number: MO41787 Start Date*: 2021-04-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIIb, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUS EMICIZUMAB IN PATIENTS FROM BIRTH TO 12 MONTHS OF AG...
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10053753 Hemophilia A without inhibitors LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Ongoing) AT (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005092-13 Sponsor Protocol Number: MO42623 Start Date*: Information not available in EudraCT
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, OPEN-LABEL PHASE IV STUDY TO EVALUATE OVERALL HEALTH, PHYSICAL ACTIVITY, AND JOINT OUTCOMES, IN PARTICIPANTS AGED ≥ 13 AND < 70 YEARS WITH SEVERE OR MODERATE HEMOPHILIA A WITHOUT FVI...
    Medical condition: Severe or Moderate Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10053753 Hemophilia A without inhibitors LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) DE (Ongoing) ES (Ongoing) IT (Ongoing) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003293-18 Sponsor Protocol Number: RGHT000470 Start Date*: 2009-03-16
    Sponsor Name:Belfast Health and Social Care Trust [...]
    1. Belfast Health and Social Care Trust
    2. Queen's University Belfast
    Full Title: Pharmacokinetics of ketamine in infants
    Medical condition: Pharmacokinetics of ketamine in infants
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021723 Induction and maintenance of anaesthesia LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002866-21 Sponsor Protocol Number: BH29884 Start Date*: 2016-01-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS ...
    Medical condition: Hemophilia A with Inhibitors
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10060612 Hemophilia A LLT
    19.1 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004296-35 Sponsor Protocol Number: RGHT000203 Start Date*: 2007-10-18
    Sponsor Name:The Royal Group of Hospitals, Belfast Health and Social Care Trust [...]
    1. The Royal Group of Hospitals, Belfast Health and Social Care Trust
    2. Queen's University Belfast
    Full Title: An investigation into the modulation of obesity associated monocyte/macrophage function, vascular inflammation and insulin resistance by PPAR agonist treatment
    Medical condition: The proposed study will investigate early indicators of cardiovascular disease and diabetes in healthy, obese men without a family history of diabetes and whether these are changed by treatment wit...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:03:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA